Table 1.
Clinicopathological characteristics and treatment of the BCBM patients
| n | % | ||
| Age at time of BCBM | Mean | 52 years | |
| SD | 10.3 | ||
| Range | 29–79 years | ||
| Gender | Female | 97 | 99.0 |
| Male | 1 | 1.0 | |
| Breast cancer subtype of BM | TNBC | 26 | 26.6 |
| HR+/HER2+ | 15 | 15.3 | |
| HR+/HER2− | 21 | 21.4 | |
| HR−/HER2+ | 36 | 36.7 | |
| Number of BM sites | 1 | 91 | 92.9 |
| 2 | 5 | 5.1 | |
| 3 or more | 2 | 2.0 | |
| KPS | 90 | 31 | 31.6 |
| 70–80 | 50 | 51.0 | |
| 60 or less | 17 | 17.4 | |
| Metastatic sites | Frontal lobe | 22 | 22.5 |
| Temporal lobe | 11 | 11.2 | |
| Parietal lobe | 5 | 5.1 | |
| Occipital lobe | 11 | 11.2 | |
| Cerebellum | 32 | 32.7 | |
| Others | 17 | 17.3 | |
| De novo stage IV breast cancer | Yes | 83 | 84.7 |
| No | 15 | 15.3 | |
| Systemic therapy after BM diagnosis | Yes | 84 | 85.7 |
| No | 14 | 14.3 | |
| Radiotherapy after BM diagnosis | Yes | 74 | 75.5 |
| No | 24 | 24.5 |
BCBM, breast cancer brain metastases; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; KPS, Karnofsky performance status; TNBC, triple-negative breast cancer.